383 Clinical exploration of microbiome-targeting strategies is accelerating, with several early-phase trials demonstrating feasibility and immunomodulatory efficacy (Table 3)
In severe acute pancreatitis, NAT10 also catalyzes the ac 4 C modification of NLRP3 mRNA, enhancing its stability and expression levels
Update, June 29, 2026: After this piece first published, the FDA posted its briefing documents for the July meeting, and its own reviewers proposed not to add BPC-157, in either of its chemical forms, to the compounding list
In the SELECT trial, patients did not enroll for the specific purpose of weight loss and received standard of care covering management of CV risk factors, including medical treatment and healthy lifestyle counseling, but without a specific focus on weight loss